Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceLakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...
- Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive DirectorLindus Therapeutics names Dr. Gillian Cannon, former Merck and Roivant commercial leader, to its board as a non-executive director.
- Collegium Pharmaceutical, Inc.Collegium to Participate in Upcoming Investor ConferencesCollegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences:
- Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceCalidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.
- Avalyn Pharma Inc.Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceAvalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 14, 2026, at 1:50-2:25 p.m. ET.
- Anavex Life Sciences Corp.Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ETAnavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026, during which Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company’s clinical development strategy and priorities.
- Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceFortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on Friday, September 11, 2026, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference taking place September 14-16, 2026.
- Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune DiseaseOrikine Bio (“Orikine”), a biotechnology company pioneering bi-specific cytokines to reprogram the immune system and treat autoimmune and chronic inflammatory disease, today announced changes to its leadership team to support the next stage of corporate development. Sabrina Kuttruff-Coqui, Ph.D., has been appointed Chief Executive Officer, and Joachim Koch, Ph.D., has been appointed Chief Scientific Officer and Chief Development Officer. Both bring decades of biotechnology industry experience to accelerate Orikine's growth strategy and advance Orikine's pipeline. Andreas Muehler, MD, MBA, joins as part-time Chief Medical Officer, bringing a strong medical track record for the transition of lead candidate ORK1 toward an IND submission and first-in-human studies. Pilar Casado García will continue to serve as Chief Financial Officer, ensuring financial and institutional continuity. The Orikine team is expanding at a critical inflection point, as ORK1 advances from preclinical research to IND-enabling studies in inflammatory bowel disease.
- Epicyt Pharma reports positive results in first-in-human study of BAFA in patients following gastric bypass surgeryEpicyt Pharma AB, a Gothenburg-based clinical-stage biopharmaceutical company developing therapies for impaired intestinal calcium uptake, today announced positive topline results from its Phase 1/2a first-in-human study of BAFA in...
- Defence Therapeutics Inc.Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to ShareholdersDefence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward. Dear...
- Schall, Brown & Schwartz LLPCAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawSchall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a)...
- DJS Law Group LLPCapricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRThe DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated...